コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ith respect to recipient characteristics and HLA matching.
2 reduce CIT and DGF while achieving excellent HLA matching.
3 AZA and MMF treated patients with increased HLA matching.
4 ller than may be achievable through expanded HLA matching.
5 from significantly older donors with poorer HLA matching.
6 re greater than the advantages of optimizing HLA matching.
7 comparatively more severe than that of poor HLA matching.
8 donor-recipient relationship, and degree of HLA matching.
9 the clinical implications of donor-recipient HLA matching.
10 lability and less stringent requirements for HLA matching.
11 haplo donors based upon criteria other than HLA matching.
12 up (acute leukemia), allowing all degrees of HLA matching.
13 gely achieve the principal goal of improving HLA matching.
14 atus were as predictive of survival as donor HLA matching.
15 ld provide the maximum practical benefit for HLA matching.
16 gradual incremental benefit with respect to HLA matching.
17 ient survival is greater than that seen with HLA matching.
18 ors were recipients' siblings with excellent HLA matching.
19 nor serostatus in the era of high-resolution HLA matching.
20 antigenic epitopes without the necessity of HLA matching.
21 HLA-specific sensitization than conventional HLA matching.
22 considering removing the points awarded for HLA matching.
23 waiting times over human leukocyte antigen (HLA) matching.
25 g of the HLA system and the requirements for HLA matching; 3) improved methods for acquisition, stora
28 ipient functional HLA matching as opposed to HLA matching alone, however, was important for tumor res
29 ated with a higher degree of donor-recipient HLA matching, although a difference in the frequency of
30 nt in kidney-transplant recipients with good HLA matching: among 326 recipients who received well-mat
32 ime period, in which patients had equivalent HLA matching and immunosuppression and a minimum of 5 ye
33 location alliance has improved the degree of HLA matching and increased the exchange of organs, witho
36 of blood disorders, even with optimal donor HLA matching and use of prophylactic immunosuppressive a
37 of the criteria for human leukocyte antigen (HLA) matching and simulation evidence about the effectiv
38 association between human leukocyte antigen (HLA) matching and the development of GvHD after cadaveri
39 oup defined terms for HLA typing resolution, HLA matching, and a format for reporting HLA assignments
40 er donors offset the disadvantages of poorer HLA matching, and better HLA matching offsets the disadv
42 or, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transpla
43 erformance status, degree of donor-recipient HLA matching, and disease type and status at transplanta
44 including age, duration of first remission, HLA matching, and graft-versus-host (GVH) disease, were
45 resistance, and immunologic variables (ABO, HLA matching, and pretransplant anti-HLA antibodies).
46 ipients tended to be older, to have inferior HLA matching, and to have older donors than did the LRD
48 conjunction with donor/recipient functional HLA matching as opposed to HLA matching alone, however,
52 study was designed to determine how class I HLA matching at the triplet level affects kidney transpl
54 ct of donor age and human leukocyte antigen (HLA) matching because these are variables that may help
56 Schizophrenia and human leukocyte antigen (HLA) matching between couples or between mothers and off
58 vere aplastic anemia subtype, recipient age, HLA matching, calendar year of transplant, and condition
60 use, conditioning regimens, ganciclovir use, HLA matching, circulating CMV antigenemia, absolute CD4+
61 ed kidneys and the effects of changes to the HLA matching criteria on graft survival and the distribu
62 To our knowledge, this is the first PGD with HLA matching, demonstrating feasibility of preselecting
64 obviate the benefits of HLA matching, while HLA matching does not minimize the benefits of MMF on lo
65 ded underlying disease type, donor-recipient HLA matching, donor CMV serostatus, and age as a continu
66 the UK of exchanging kidneys on the basis of HLA matching, especially to recipients when there is a 0
67 The degree of blood group compatibility and HLA matching for a recipient population consisting of 65
76 Since then, the stringency of criteria for HLA matching have been liberalized twice, from sharing o
78 vs 40%, P = .003) irrespective of degree of HLA matching (HLA 10/10 match: 75% vs 39%, P = .02) and
79 ed successfully even in the presence of poor HLA matching if an aggressive approach were taken with r
92 ce less emphasis on human leukocyte antigen (HLA) matching in pediatric kidney transplant candidates
93 The importance of human leukocyte antigen (HLA) matching in renal transplantation is well recognize
94 The importance of human leukocyte antigen (HLA) matching in unrelated donor transplantation for non
98 ld be distributed nationally, because better HLA matching is associated with improved short-term graf
99 for younger patients while recognizing that HLA matching is less important for older patients as ret
100 ts will undergo immune rejection even though HLA matching is not routinely performed and the use of i
102 further selected on the basis of older age, HLA-matching, low allosensitization, and low body mass i
103 portion of African-Americans, lower rates of HLA matching, lower levels of panel-reactive antibodies,
107 t function had significantly less degrees of HLA matching (mean 1.5) in comparison to patients with g
108 Our data do not support the concept that KIR-HLA matching might serve as a tool to improve long-term
109 list and resulted in significantly improved HLA matching, more than doubling the proportion of trans
111 gnificant difference between PCAR and CAR in HLA matching, occurrence of posttransplant acute tubular
113 ients might be negatively impacted from poor HLA matching of their first kidney transplant when needi
115 dvantages of poorer HLA matching, and better HLA matching offsets the disadvantages of older donor ag
116 Although there might be a limited impact of HLA matching on acute rejection and graft survival, many
117 of this study was to determine the effect of HLA matching on deceased and LD renal allograft outcomes
118 o investigate the effects of donor-recipient HLA matching on graft survival in pediatric heart transp
120 etrospectively the effect of donor-recipient HLA matching on outcomes of single umbilical-cord blood
124 of donor-recipient human leukocyte antigen (HLA) matching on outcomes remains relatively unexplored
125 y four odorants was significantly related to HLA matching (P < 10(-4)), such that olfactory fingerpri
127 of these alternatives compared with present HLA-matching practices, and to assess the relative effec
128 pe, Karnofsky performance score, graft type, HLA matching, prior aplastic anemia therapy, race/ethnic
132 hod, and stratified by site, donor-recipient HLA matching status, and donor's cytomegalovirus serosta
133 e is to evaluate superiority of the proposed HLA matching strategy in comparison to random graft assi
135 atric patients achieved comparable levels of HLA matching to adult patients for the first time in the
136 beyond those of prenatal diagnosis, such as HLA matching to affected siblings to provide stem cell t
137 ary importance is sufficient donor-recipient HLA matching to ensure engraftment and acceptable rates
144 graft loss was observed in patients with no HLA matching whatsoever in comparison to patients with a
145 dies have reported diminishing importance of HLA matching, which have, in turn, been challenged by re
146 use of MMF does not obviate the benefits of HLA matching, while HLA matching does not minimize the b
147 tric donor-recipient pairs with allele-level HLA matching who received a single unit umbilical cord b
148 urvival; (2). Removing the consideration for HLA matching will result in fewer transplant opportuniti
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。